Clinical trials: Gut
Healthy
Exploratory Study of Circadian Relationships Between Social Behavior, Blood Pressure and Metabolomics
As citizens of the information age, humans leave digital traces of behavior in their communication and movement patterns through our cell phone.
- Trial name
- NCT02249793
- Where
- United States
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- University of Pennsylvania
Metastatic Pancreatic Cancer, Unresectable Pancreatic Cancer
EL CENTRO: Engaging Latinos in the Center of Cancer Treatment Options
The objective of this study is to improve the chemotherapy decision making process for Latinos with advanced gastrointestinal cancers.
- Conditions
- Metastatic Pancreatic Cancer, Unresectable Pancreatic Cancer, Metastatic Colorectal Cancer
- Trial name
- NCT03602885
- Testing
- Usual chemotherapy education (CE), Chemotherapy education intervention (CEI)
- Where
- 5 sites in United States
- Volunteers
- 10 people
- Sponsor
- Dana-Farber Cancer Institute
Gastric Ulcer, Duodenal Ulcer
Long Term Study to Investigate the Efficacy & Safety of D961H (Esomeprazole) for the Prevention of NSAIDs-induced Ulcer
The purpose of this study is to assess the Safety and tolerability of D961H (Esomeprazole) 20 mg once daily for up to 52 weeks of treatment involving patients with a history of gastric and/or duodenal ulcers receiving daily…
- Conditions
- Gastric Ulcer, Duodenal Ulcer, Rheumatoid Arthritis, Osteoarthritis
- Trial name
- NCT00595517
- Testing
- Esomeprazole 20 mg
- Where
- 3 sites in Japan
- Volunteers
- 395 people
- Sponsor
- AstraZeneca
Ulcerative Colitis
Generate Real World Data On Tofacitinib Induction Therapy and Changes In Clinical and Patient Reported Outcomes.
This study is expected to contribute to the body of real-world data of tofacitinib's safety and efficacy profile in ulcerative colitis.
- Trial name
- KIC-START (NCT05069259)
- Testing
- Stool sample collection
- Where
- 5 sites in Switzerland
- Volunteers
- 18 people
- Sponsor
- Pfizer
Ulcerative Colitis, Crohn's Disease
A Phase I Study of Etrolizumab Followed by Open-Label Extension and Safety Monitoring in Pediatric Patients With Moderate to Severe Ulcerative Colitis or Moderate to Severe Crohn's Disease
This study will evaluate pharmacokinetics, pharmacodynamics and safety of etrolizumab in pediatric patients of 4 to <18 years of age with moderate to severe ulcerative colitis (UC) or with moderate to severe Crohn's disease (CD).
- Trial name
- FENNEL (NCT03478956)
- Testing
- Etrolizumab
- Where
- 5 sites in Belgium, Poland and 2 more
- Volunteers
- 24 people
- Sponsor
- Hoffmann-La Roche
Neoplasms, Colorectal Neoplasms
Study of MK-1697 in Participants With Advanced Solid Tumors (MK-1697-001)
The purpose of this study is to evaluate the safety and preliminary efficacy of MK-1697. There are 2 parts in this study: dose escalation to determine the recommended phase 2 dose (RP2D) and confirm the RP2D (Part A) and cohort…
- Conditions
- Neoplasms, Colorectal Neoplasms, Head and Neck Neoplasms
- Trial name
- NCT03515824
- Testing
- MK-1697
- Where
- 2 sites in Australia, Hong Kong
- Volunteers
- 22 people
- Sponsor
- Merck Sharp & Dohme LLC
Rectal Neoplasms, Fecal Incontinence
The Role of Biofeedback in Improving Continence After Anterior Resection
The purpose of this study is to determine whether biofeedback exercises improve anal continence after anterior resection for rectal cancer.
- Conditions
- Rectal Neoplasms, Fecal Incontinence, Aged
- Trial name
- NCT00515853
- Testing
- Biofeedback
- Where
- United Kingdom
- Volunteers
- 121 people
- Sponsor
- University of Southampton
Colorectal Cancer
Accelerating Colorectal Cancer Screening Through Implementation Science in Appalachia
This project aims to implement a multi-level group randomized trial, delayed intervention that includes components targeting clinics, providers, patients, and the community to increase colorectal cancer (CRC) screening…
- Trial name
- ACCSIS (NCT04427527)
- Testing
- Multi-level intervention to increase CRC screening
- Where
- 2 sites in United States
- Volunteers
- 29,772 people, healthy volunteers welcome
- Sponsor
- Mark Dignan, PhD
Melanoma, Carcinoma, Hepatocellular
A Study of E7386 in Combination With Pembrolizumab in Previously Treated Participants With Selected Solid Tumors
The Phase 1b part of this study is conducted to assess the safety and tolerability of E7386 in combination with pembrolizumab in participants with previously treated selected solid tumors, and to determine the recommended Phase 2…
- Conditions
- Melanoma, Carcinoma, Hepatocellular, Colorectal Neoplasms
- Trial name
- NCT05091346
- Testing
- E7386, Pembrolizumab, Lenvatinib
- Where
- 32 sites in United States, Japan and 2 more
- Volunteers
- 89 people
- Sponsor
- Eisai Inc.
Ulcerative Colitis
Safety and Efficacy of Asacol 4.8 g/Day Versus Asacol 2.4 g/Day (ASCEND I)
The purpose of this study is to evaluate the safety and efficacy of Asacol 4.8 g/day (800 mg tablet) versus Asacol 2.4 g/day (400 mg tablet
- Trial name
- ASCEND I (NCT00577473)
- Testing
- mesalamine
- Where
- 44 sites in United States
- Volunteers
- 301 people
- Sponsor
- Warner Chilcott
Human Gastrointestinal Physiology Data
Modernization of in vivo-in Vitro Oral Bioperformance Prediction and Assessment
In vivo drug dissolution in the gastrointestinal (GI) tract is largely unmeasured. The purpose of this clinical study was to evaluate the in vivo drug dissolution and systemic absorption of the BCS Class IIa drug ibuprofen under…
- Trial name
- NCT02806869
- Testing
- Single dose of ibuprofen (800 mg tablet), Pulmocare, two 8.0 oz (236.6 mL) cans
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- University of Michigan
Ulcerative Colitis
Etrasimod Versus Placebo for the Treatment of Moderately to Severely Active Ulcerative Colitis
The purpose of this study is to determine whether oral etrasimod is a safe and effective treatment for moderately to severely active ulcerative colitis.
- Trial name
- ELEVATE UC 52 (NCT03945188)
- Testing
- Etrasimod
- Where
- 315 sites in United States, Argentina and 38 more
- Volunteers
- 433 people
- Sponsor
- Arena Pharmaceuticals
Lymphoma
SAHA + CHOP in Untreated T-cell Non-Hodgkin's Lymphoma
The goal of this clinical research study is to find out how well the drug Zolinza (vorinostat) works in combination with the drug combination called CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) to treat…
- Trial name
- NCT00787527
- Testing
- Zolinza (vorinostat), Cyclophosphamide, Doxorubicin
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- M.D. Anderson Cancer Center
Ileus
Intermountain Healthcare's Enhanced Recovery Protocol for Colon Surgery With and Without Alvimopan Use
The purpose of this study is to determine if the addition of alvimopan to our care process model for colon resection patients will decrease length of stay.
- Trial name
- NCT01143259
- Testing
- Alvimopam, 300 mg Polyethylene
- Where
- 9 sites in United States
- Volunteers
- 274 people
- Sponsor
- Intermountain Health Care, Inc.
Neuropathy, Painful, Chemotherapy-induced Peripheral Neuropathy
Lidocaine for Oxaliplatin-induced Neuropathy
Oxaliplatin-induced neuropathy is a major dose-limiting side effect in patients with colorectal cancer treated with the FOLFOX chemotherapy regimen.
- Conditions
- Neuropathy, Painful, Chemotherapy-induced Peripheral Neuropathy, Colorectal Cancer
- Trial name
- NCT03254394
- Testing
- Lidocaine Hydrochloride, FOLFOX regimen
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Washington University School of Medicine
Melanoma, Renal Cell Carcinoma
A Dose Escalation and Cohort Expansion Study of NKTR-214 in Combination With Nivolumab and Other Anti-Cancer Therapies in Patients With Select Advanced Solid Tumors
In this four-part study, NKTR-214 was administered in combination with nivolumab and with/without other anticancer therapies. Part 1 considered escalating doublet (NKTR 214 + nivolumab) doses to determine the RP2D.
- Conditions
- Melanoma, Renal Cell Carcinoma, Non Small Cell Lung Cancer, Urothelial Carcinoma
- Trial name
- PIVOT-02 (NCT02983045)
- Testing
- Dose Escalation Doublet: Combination of NKTR-214 + nivolumab, Dose Expansion Doublet: Combination of NKTR-214 + nivolumab, Schedule Finding Triplet: Combination of NKTR-214+ nivolumab+ ipilimumab
- Where
- 58 sites in United States, Belgium and 6 more
- Volunteers
- 557 people
- Sponsor
- Nektar Therapeutics
Melanoma (Skin), Melanoma
Pembrolizumab and EDP1503 in Advanced Melanoma
This study is being done to determine if orally administered EDP1503 will enhance the response to standard immunotherapy treatment (pembrolizumab) in participants with advanced melanoma.
- Trial name
- NCT03595683
- Testing
- Pembrolizumab, EDP1503
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- University of Chicago
Osteoporosis, Osteopenia
Does Treatment of Hypovitaminosis D Increase Calcium Absorption?
The purpose is to perform a one-year study designed to assess whether treatment of hypovitaminosis D increases intestinal absorption of calcium, subsequent retention of calcium within bone, decreases bone turnover, and favorably…
- Conditions
- Osteoporosis, Osteopenia, Vitamin D Deficiency, Hypoparathyroidism
- Trial name
- NCT00581828
- Testing
- Vitamin D
- Where
- United States
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- University of Wisconsin, Madison
Urea Cycle Disorder
Manipulating the Gut Microbiome Study
The objective is to determine if acetohydroxamic acid (AHA) can prevent hydrolysis of urea by inhibiting the bacterial urease of gut flora of both healthy control adults as well as adults with urea cycle disorders
- Trial name
- NCT03181828
- Testing
- Acetohydroxamic Acid Oral Tablet, No treatment
- Where
- United States
- Volunteers
- 4 people, healthy volunteers welcome
- Sponsor
- Nicholas Ah Mew
Appendicitis, Surgery
Sugammadex vs Neostigmine Reversal in Pediatric Appendectomy
This study is designed as a randomized controlled trial with patients assigned to neuromuscular reversal with either sugammadex or neostigmine/glycopyrrolate reversal.
- Trial name
- NCT05256901
- Testing
- Sugammadex, Neostigmine/Glycopyrrolate
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Emory University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.